Published 1 year ago

Pfizer inks $43 billion Seagen deal to boost cancer portfolio

Summary by RTÉ

Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.

0 Articles

All

Left

Center

Right

Times of India

Pfizer will spend $43 billion to acquire Seagen

"Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen's antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer's capabilities and expertise," Pfizer Chairman and CEO Dr. Albert Bourla said in a statement.

1 year ago·India

Read Full Article

News18 India

Pfizer to Acquire Seagen For $43 bn To Deepen Reach into Treating Cancer

Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients, says Pfizer CEO

1 year ago·India

Read Full Article

Reuters

Pfizer looks past COVID with $43 bln deal for cancer drug maker Seagen

Pfizer Inc on Monday struck a $43 billion deal to acquire Seagen Inc and its targeted cancer therapies as it braces for a steep fall in COVID-19 sales and generic competition for some top-selling drugs.

1 year ago·United Kingdom

Read Full Article

Associated Press News

Pfizer buys Seagen for $43B, boosts access to cancer drugs

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue. The pharmaceutical giant said Monday it will pay

1 year ago·United States

Read Full Article